Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDS ...Middle East

PR Newswire - News
Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDS
EMA accelerated assessment allows a shorter review period for leniolisib from a standard 210 days to 150 days Pharming is on track to submit its Marketing Authorisation Application for leniolisib in H2 2022 LEIDEN, the Netherlands, Aug. 1, 2022 /PRNewswire/ -- Pharming Group N.V....

Hence then, the article about pharming group receives accelerated assessment in europe for leniolisib for the treatment of rare immunodeficiency apds was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDS )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News